001     177909
005     20240229133754.0
024 7 _ |a 10.1111/apt.16405
|2 doi
024 7 _ |a pmid:34004036
|2 pmid
024 7 _ |a 0269-2813
|2 ISSN
024 7 _ |a 0953-0673
|2 ISSN
024 7 _ |a 1365-2036
|2 ISSN
024 7 _ |a altmetric:106081708
|2 altmetric
037 _ _ |a DKFZ-2021-02931
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Chandrapalan, Subashini
|0 0000-0002-1582-3224
|b 0
245 _ _ |a Systematic review with meta-analysis: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer.
260 _ _ |a Oxford
|c 2021
|b Wiley-Blackwell
264 _ 1 |3 online
|2 Crossref
|b Wiley
|c 2021-05-18
264 _ 1 |3 print
|2 Crossref
|b Wiley
|c 2021-07-01
264 _ 1 |3 print
|2 Crossref
|b Wiley
|c 2021-07-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1639052066_22604
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Faecal immunochemical test (FIT) is emerging as a valid test to rule-out the presence of colorectal cancer (CRC). However, the accuracy of FIT is dependent on the cut-off applied. An additional low-cost test could improve further detection of CRC.To evaluate the efficacy of combined FIT and volatile organic compounds (VOC) in the detection of CRC within symptomatic populations.Systematic reviews on the diagnostic accuracy of FIT and VOC, for the detection of CRC, were updated. Meta-analyses were performed adopting a bivariate model for sensitivity and specificity. Clinical utility of combined FIT and VOC was estimated using Fagan's nomogram. Post-test probability of FIT negatives was used as a pre-test probability for VOC.The pooled sensitivity and specificity of FIT at 10 µg/g faeces, for the detection of CRC, were 0.914 (95% confidence interval [CI] = 0.894-0.936) and 0.783 (CI = 0.850-0.696), respectively. For VOC, the sensitivity was 0.837 (CI = 0.781-0.881) and the specificity was 0.803 (CI = 0.870-0.712). The area under the curve for FIT and VOC were 0.926 and 0.885, respectively. In a population with 5% CRC prevalence, the estimated probability of having CRC following a negative FIT was 0.5% and following both negative FIT and VOC was 0.1%.In a FIT-negative symptomatic population, VOC can be a good test to rule-out the presence of CRC. The estimated probability reduction by 0.4% when both tests being negative offers adequate safety netting in primary care for the exclusion of CRC. The number needed to colonoscope to identify one CRC is eight if either FIT or VOC positive. Cost-effectiveness and clinical accuracy of this approach will need further evaluation.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
542 _ _ |i 2021-05-18
|2 Crossref
|u http://creativecommons.org/licenses/by-nc/4.0/
542 _ _ |i 2021-05-18
|2 Crossref
|u http://doi.wiley.com/10.1002/tdm_license_1.1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Volatile Organic Compounds
|2 NLM Chemicals
650 _ 2 |a Colorectal Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Early Detection of Cancer
|2 MeSH
650 _ 2 |a Feces
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Occult Blood
|2 MeSH
650 _ 2 |a Sensitivity and Specificity
|2 MeSH
650 _ 2 |a Volatile Organic Compounds
|2 MeSH
700 1 _ |a Bosch, Sofie
|0 0000-0001-9202-1674
|b 1
700 1 _ |a Cubiella, Joaquín
|0 0000-0002-9994-4831
|b 2
700 1 _ |a Guardiola, Jordi
|b 3
700 1 _ |a Kimani, Peter
|b 4
700 1 _ |a Mulder, Chris
|b 5
700 1 _ |a Persaud, Krishna
|b 6
700 1 _ |a de Meij, Tim G J
|b 7
700 1 _ |a Altomare, Donato F
|b 8
700 1 _ |a Brenner, Herman
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 9
|u dkfz
700 1 _ |a de Boer, Nanne K H
|b 10
700 1 _ |a Ricciardiello, Luigi
|0 0000-0003-2568-6208
|b 11
700 1 _ |a Arasaradnam, Ramesh P
|0 0000-0002-2231-3062
|b 12
773 1 8 |a 10.1111/apt.16405
|b Wiley
|d 2021-05-18
|n 1
|p 14-23
|3 journal-article
|2 Crossref
|t Alimentary Pharmacology & Therapeutics
|v 54
|y 2021
|x 0269-2813
773 _ _ |a 10.1111/apt.16405
|g Vol. 54, no. 1, p. 14 - 23
|0 PERI:(DE-600)2003094-0
|n 1
|p 14-23
|t Alimentary pharmacology & therapeutics
|v 54
|y 2021
|x 0269-2813
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177909
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALIMENT PHARM THER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALIMENT PHARM THER : 2015
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a UNRESTRICTED
999 C 5 |1 NICE, National Collaborating Centre for Cancer
|y 2015
|2 Crossref
|t Suspected Cancer: Recognition and Referral. NICE Guideline
|o NICE, National Collaborating Centre for Cancer Suspected Cancer: Recognition and Referral. NICE Guideline 2015
999 C 5 |1 Stonestreet J
|y 2019
|2 Crossref
|o Stonestreet J 2019
999 C 5 |a 10.1136/flgastro-2018-101174
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1016/j.gie.2014.08.006
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1097/CEJ.0000000000000281
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1001/jamainternmed.2017.2309
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1038/s41395-018-0212-7
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1016/j.cgh.2020.01.025
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.14309/ajg.0000000000000465
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1002/bjs.8942
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/codi.14739
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/codi.14431
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1002/ijc.29701
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1097/MD.0000000000020937
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |1 The Cochrane Collaboration
|2 Crossref
|t Handbook for DTA Reviews. Cochrane Screening and Diagnostic Tests
|o The Cochrane Collaboration Handbook for DTA Reviews. Cochrane Screening and Diagnostic Tests
999 C 5 |a 10.1038/clpt.2010.229
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |1 R Core Team
|y 2020
|2 Crossref
|t A language and environment for statistical computing
|o R Core Team A language and environment for statistical computing 2020
999 C 5 |2 Crossref
|u DoeblerP.mada: meta‐analysis of diagnostic accuracy. R package version 0.5.10;2020.https://rdrr.io/rforge/mada/. Accessed December 20 2020.
999 C 5 |a 10.1056/NEJM197507312930513
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1080/00365521.2016.1228120
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1136/gutjnl-2015-309579
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1136/gutjnl-2020-321956
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/codi.15405
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/apt.15969
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.3389/fmed.2020.00410
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1080/00365521.2019.1708965
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1177/2050640613489281
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/apt.13865
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1177/2050640614553285
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1515/cclm-2015-0617
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1016/j.dld.2015.05.004
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1158/1055-9965.EPI-10-0848
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/codi.14944
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1177/0004563220935622
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1007/s10151-019-01963-6
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1016/j.bios.2014.10.044
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/apt.15622
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1002/bjs5.50354
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/codi.15009
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1371/journal.pone.0108750
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1371/journal.pone.0130301
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1111/apt.15140
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1002/ijc.28446
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1002/ags3.12056
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.3310/hta21330
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1007/s11306-020-01735-6
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1080/14737159.2020.1738928
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1088/1752-7163/ab2775
|9 -- missing cx lookup --
|2 Crossref
999 C 5 |a 10.1371/journal.pone.0203359
|9 -- missing cx lookup --
|2 Crossref


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21